Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure
Apart from the well-established adverse musculoskeletal and sexual health effects of androgen deprivation therapy (ADT), evidence is accumulating of substantial ADT-related cardiovascular and metabolic complications, which may impact quality of life and overall survival. In this brief review we disc...
Gespeichert in:
| Veröffentlicht in: | Prostate cancer and prostatic diseases 2009-09, Vol.12 (3), p.233-240 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 240 |
|---|---|
| container_issue | 3 |
| container_start_page | 233 |
| container_title | Prostate cancer and prostatic diseases |
| container_volume | 12 |
| creator | Galvão, D A Taaffe, D R Spry, N Joseph, D Newton, R U |
| description | Apart from the well-established adverse musculoskeletal and sexual health effects of androgen deprivation therapy (ADT), evidence is accumulating of substantial ADT-related cardiovascular and metabolic complications, which may impact quality of life and overall survival. In this brief review we discuss (1) the incidence of cardiovascular and metabolic complications during/following ADT from large cohort studies, (2) the increased risk factors for cardiovascular and metabolic disease from cross-sectional and prospective studies and (3) the use of physical exercise as a countermeasure in this new era of ADT-related toxicity. It is clear that exercise has the potential to provide a myriad of benefits to men undergoing ADT that may result in reduced morbidity and mortality, and subsequently improve quality of life. |
| doi_str_mv | 10.1038/pcan.2009.12 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_20941839</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A207745006</galeid><sourcerecordid>A207745006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-960110333775499d8bf883bd8563d9652bb4f062fda10ee1376d0adeb2744d893</originalsourceid><addsrcrecordid>eNp1kk1r3DAQhk1padJtbz0X00JO9VbflnILS78g0Et7FrI03ijYkivZof33lbML25QUgWaQnnmlYd6qeo3RFiMqP0zWhC1BSG0xeVKdY9aKhgskn5acCt60kpOz6kXOt6hAWKHn1RlWTEok2vMq7ExyPt6ZbJfBpNoEV48wmy4O3tY2jlOJZvYx5NotyYf9iqS4h1A7mJK_u7-8rOEXJOsz1CbXpp7iDGH2ZigSS5ghjWDykuBl9aw3Q4ZXx7ipfnz6-H33pbn-9vnr7uq6sRzjuVEC4dIcpW3LmVJOdr2UtHOSC-qU4KTrWI8E6Z3BCADTVjhkHHSkZcxJRTfVxUF3SvHnAnnWo88WhsEEiEvWBCmGJV3Bd_-At3FJofxNE8E4xZKXfVO9_S9FFGKtJOgktTcDaB_6OCdj13f1FUFtyzhColDbR6iyHIzexgC9L-cPCi7-KrgBM8w3OQ7L_Uwegu8PoE0x5wS9LuMZTfqtMdKrVfRqFb1aRWNS8DfHnpZuBHeCj94oQHMA8rTOHdKp6UcF_wBwJcbn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229047820</pqid></control><display><type>article</type><title>Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Galvão, D A ; Taaffe, D R ; Spry, N ; Joseph, D ; Newton, R U</creator><creatorcontrib>Galvão, D A ; Taaffe, D R ; Spry, N ; Joseph, D ; Newton, R U</creatorcontrib><description>Apart from the well-established adverse musculoskeletal and sexual health effects of androgen deprivation therapy (ADT), evidence is accumulating of substantial ADT-related cardiovascular and metabolic complications, which may impact quality of life and overall survival. In this brief review we discuss (1) the incidence of cardiovascular and metabolic complications during/following ADT from large cohort studies, (2) the increased risk factors for cardiovascular and metabolic disease from cross-sectional and prospective studies and (3) the use of physical exercise as a countermeasure in this new era of ADT-related toxicity. It is clear that exercise has the potential to provide a myriad of benefits to men undergoing ADT that may result in reduced morbidity and mortality, and subsequently improve quality of life.</description><identifier>ISSN: 1365-7852</identifier><identifier>EISSN: 1476-5608</identifier><identifier>DOI: 10.1038/pcan.2009.12</identifier><identifier>PMID: 19488067</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Androgen Antagonists - adverse effects ; Androgens ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cardiovascular diseases ; Cardiovascular Diseases - etiology ; Care and treatment ; Complications ; Complications and side effects ; Deprivation ; Diagnosis ; Exercise ; Health aspects ; Health risks ; Humans ; Male ; Metabolic Diseases - etiology ; Metabolic disorders ; Metabolism ; Morbidity ; Physical exercise ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Quality of life ; review ; Risk analysis ; Risk Factors ; Toxicity</subject><ispartof>Prostate cancer and prostatic diseases, 2009-09, Vol.12 (3), p.233-240</ispartof><rights>Springer Nature Limited 2009</rights><rights>COPYRIGHT 2009 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Sep 2009</rights><rights>Nature Publishing Group 2009.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-960110333775499d8bf883bd8563d9652bb4f062fda10ee1376d0adeb2744d893</citedby><cites>FETCH-LOGICAL-c511t-960110333775499d8bf883bd8563d9652bb4f062fda10ee1376d0adeb2744d893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/pcan.2009.12$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/pcan.2009.12$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19488067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galvão, D A</creatorcontrib><creatorcontrib>Taaffe, D R</creatorcontrib><creatorcontrib>Spry, N</creatorcontrib><creatorcontrib>Joseph, D</creatorcontrib><creatorcontrib>Newton, R U</creatorcontrib><title>Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure</title><title>Prostate cancer and prostatic diseases</title><addtitle>Prostate Cancer Prostatic Dis</addtitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><description>Apart from the well-established adverse musculoskeletal and sexual health effects of androgen deprivation therapy (ADT), evidence is accumulating of substantial ADT-related cardiovascular and metabolic complications, which may impact quality of life and overall survival. In this brief review we discuss (1) the incidence of cardiovascular and metabolic complications during/following ADT from large cohort studies, (2) the increased risk factors for cardiovascular and metabolic disease from cross-sectional and prospective studies and (3) the use of physical exercise as a countermeasure in this new era of ADT-related toxicity. It is clear that exercise has the potential to provide a myriad of benefits to men undergoing ADT that may result in reduced morbidity and mortality, and subsequently improve quality of life.</description><subject>Androgen Antagonists - adverse effects</subject><subject>Androgens</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Care and treatment</subject><subject>Complications</subject><subject>Complications and side effects</subject><subject>Deprivation</subject><subject>Diagnosis</subject><subject>Exercise</subject><subject>Health aspects</subject><subject>Health risks</subject><subject>Humans</subject><subject>Male</subject><subject>Metabolic Diseases - etiology</subject><subject>Metabolic disorders</subject><subject>Metabolism</subject><subject>Morbidity</subject><subject>Physical exercise</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Quality of life</subject><subject>review</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Toxicity</subject><issn>1365-7852</issn><issn>1476-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kk1r3DAQhk1padJtbz0X00JO9VbflnILS78g0Et7FrI03ijYkivZof33lbML25QUgWaQnnmlYd6qeo3RFiMqP0zWhC1BSG0xeVKdY9aKhgskn5acCt60kpOz6kXOt6hAWKHn1RlWTEok2vMq7ExyPt6ZbJfBpNoEV48wmy4O3tY2jlOJZvYx5NotyYf9iqS4h1A7mJK_u7-8rOEXJOsz1CbXpp7iDGH2ZigSS5ghjWDykuBl9aw3Q4ZXx7ipfnz6-H33pbn-9vnr7uq6sRzjuVEC4dIcpW3LmVJOdr2UtHOSC-qU4KTrWI8E6Z3BCADTVjhkHHSkZcxJRTfVxUF3SvHnAnnWo88WhsEEiEvWBCmGJV3Bd_-At3FJofxNE8E4xZKXfVO9_S9FFGKtJOgktTcDaB_6OCdj13f1FUFtyzhColDbR6iyHIzexgC9L-cPCi7-KrgBM8w3OQ7L_Uwegu8PoE0x5wS9LuMZTfqtMdKrVfRqFb1aRWNS8DfHnpZuBHeCj94oQHMA8rTOHdKp6UcF_wBwJcbn</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Galvão, D A</creator><creator>Taaffe, D R</creator><creator>Spry, N</creator><creator>Joseph, D</creator><creator>Newton, R U</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7TS</scope></search><sort><creationdate>20090901</creationdate><title>Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure</title><author>Galvão, D A ; Taaffe, D R ; Spry, N ; Joseph, D ; Newton, R U</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-960110333775499d8bf883bd8563d9652bb4f062fda10ee1376d0adeb2744d893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Androgen Antagonists - adverse effects</topic><topic>Androgens</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Care and treatment</topic><topic>Complications</topic><topic>Complications and side effects</topic><topic>Deprivation</topic><topic>Diagnosis</topic><topic>Exercise</topic><topic>Health aspects</topic><topic>Health risks</topic><topic>Humans</topic><topic>Male</topic><topic>Metabolic Diseases - etiology</topic><topic>Metabolic disorders</topic><topic>Metabolism</topic><topic>Morbidity</topic><topic>Physical exercise</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Quality of life</topic><topic>review</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galvão, D A</creatorcontrib><creatorcontrib>Taaffe, D R</creatorcontrib><creatorcontrib>Spry, N</creatorcontrib><creatorcontrib>Joseph, D</creatorcontrib><creatorcontrib>Newton, R U</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Physical Education Index</collection><jtitle>Prostate cancer and prostatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galvão, D A</au><au>Taaffe, D R</au><au>Spry, N</au><au>Joseph, D</au><au>Newton, R U</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure</atitle><jtitle>Prostate cancer and prostatic diseases</jtitle><stitle>Prostate Cancer Prostatic Dis</stitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>12</volume><issue>3</issue><spage>233</spage><epage>240</epage><pages>233-240</pages><issn>1365-7852</issn><eissn>1476-5608</eissn><abstract>Apart from the well-established adverse musculoskeletal and sexual health effects of androgen deprivation therapy (ADT), evidence is accumulating of substantial ADT-related cardiovascular and metabolic complications, which may impact quality of life and overall survival. In this brief review we discuss (1) the incidence of cardiovascular and metabolic complications during/following ADT from large cohort studies, (2) the increased risk factors for cardiovascular and metabolic disease from cross-sectional and prospective studies and (3) the use of physical exercise as a countermeasure in this new era of ADT-related toxicity. It is clear that exercise has the potential to provide a myriad of benefits to men undergoing ADT that may result in reduced morbidity and mortality, and subsequently improve quality of life.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>19488067</pmid><doi>10.1038/pcan.2009.12</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-7852 |
| ispartof | Prostate cancer and prostatic diseases, 2009-09, Vol.12 (3), p.233-240 |
| issn | 1365-7852 1476-5608 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20941839 |
| source | MEDLINE; SpringerLink Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Androgen Antagonists - adverse effects Androgens Biomedical and Life Sciences Biomedicine Cancer Research Cardiovascular diseases Cardiovascular Diseases - etiology Care and treatment Complications Complications and side effects Deprivation Diagnosis Exercise Health aspects Health risks Humans Male Metabolic Diseases - etiology Metabolic disorders Metabolism Morbidity Physical exercise Prostate cancer Prostatic Neoplasms - drug therapy Quality of life review Risk analysis Risk Factors Toxicity |
| title | Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A07%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20and%20metabolic%20complications%20during%20androgen%20deprivation:%20exercise%20as%20a%20potential%20countermeasure&rft.jtitle=Prostate%20cancer%20and%20prostatic%20diseases&rft.au=Galv%C3%A3o,%20D%20A&rft.date=2009-09-01&rft.volume=12&rft.issue=3&rft.spage=233&rft.epage=240&rft.pages=233-240&rft.issn=1365-7852&rft.eissn=1476-5608&rft_id=info:doi/10.1038/pcan.2009.12&rft_dat=%3Cgale_proqu%3EA207745006%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229047820&rft_id=info:pmid/19488067&rft_galeid=A207745006&rfr_iscdi=true |